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objective was to study this relationship and determine whether it provides evidence
of lipid lowering therapy (LLT) effectiveness in European primary care. METHODS:
The study populations were identiﬁ ed from CSD Patient Data (France, Germany, Italy)
and THIN (UK) primary care databases. Included patients received lipid lowering 
prescription drugs in the ﬁ rst 6 months of 2005 (index) and had a prescription at least 
6 months before index. Cholesterol records within 12 months after index were 
obtained. Analyses were restricted to practitioners with cholesterol reporting rate
q50%. Multivariable linear regression was applied to evaluate the association between
cholesterol level and age controlling for gender, diabetes, cardiovascular disease,
hypertension, and LLT drug. RESULTS: In France, the median cholesterol was
5.23 mmol/L for age a65 (n  15537, 63% male) compared to 5.18 for age 65 (n 
16416, 46% male). In Germany, the median cholesterol was 5.26 mmol/L for age a65 
(n  4147, 63% male) compared to 5.10 for age 65 (n  6300, 48% male). In Italy,
the median cholesterol was 5.31 mmol/L for age a65 (n  2230, 59% male) compared
to 5.15 for age 65 (n  3232, 42% male). In the UK, the median cholesterol was 
4.50 mmol/L for age a65 (n  49,208, 61% male) compared to 4.30 for age 65 (n
 67,670, 50% male). For each country, cholesterol levels decreased with increasing
age (p  0.0001) controlling for covariates. CONCLUSIONS: This study presents 
population level evidence of LLT effectiveness in primary care as cholesterol levels did 
not increase with age, as would be expected in an untreated population. Furthermore, 
levels were lower among patients with conditions that warrant aggressive therapy
indicating LLT impact.
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OBJECTIVES: Examines the clinical and economic outcomes of this therapy modiﬁ ca-
tion in a community-based physician practice. Health care practitioners are commonly 
requested by insurers and patients to switch from their current statin to simvastatin
for cost reasons. METHODS: Medical record review via an electronic medical record
from a community-based primary care ofﬁ ce was performed on patients switched by
the physician from another statin to simvastatin between January 1, 2002 to October 
31, 2008. Patients were included if they had available lipid data pre- and post-switch.
National Cholesterol Education Program (NCEP) risk categories were calculated and
associated LDL cholesterol (LDL-C) goals assigned. Primary outcomes were changes
in lipid fractions and LDL-C goal attainment, analyzed by paired t-tests and McNe-
mar’s test, respectively. Economic outcomes were modeled using current retail medica-
tion prices and Medicare costs for medical services. RESULTS: A total of 48 patients
were identiﬁ ed; atorvastatin was the most common pre-switch statin (31 patients).
The cohort had a mean age of 64.612.6 years, was 60% female and 65% were
primary prevention. Over 95% of patients were switched to an appropriate equipotent 
dose of simvastatin. Mean pre-and post-switch LDL-C levels were 104 mg/dL and 
103 mg/dL, a non-signiﬁ cant reduction of 1.225.7 mg/dL (p  0.754). Results for the 
other lipid fractions and in a subanalysis of atorvastatin switched-patients showed
similar non-signiﬁ cant changes. A non-signiﬁ cant 4.1% increase in NCEP goal attain-
ment between the pre-switch (68.8%) and post-switch (72.9%) time periods was 
observed (p  0.754). Modeled cost savings were estimated at $575/patient/year.
CONCLUSIONS: Previously treated statin patients switched to equipotent doses of 
simvastatin achieved similar LDL-C lowering and NCEP goal attainment within this 
community-based, primary care setting. These results show the potential for signiﬁ cant 
cost savings for the health care system when appropriate patients are switched using
equipotent doses. Overall, these data support the approach that appropriate switching 
decisions should be made on a case-by-case basis.
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OBJECTIVES: Cholesterol-lowering treatment is known to reduce risk of coronary
heart disease independent of age and gender. However, the potential treatment effect 
difference of statin therapy between primary and secondary prevention trials has 
not been clearly demonstrated. This study aimed to estimate risk reduction of 
major coronary events, coronary mortality and total mortality associated with
statin drug treatment in primary and secondary prevention trials. METHODS:
Clinical trials conducted in human subjects and published in English-language journals
were collected by retrieving MEDLINE (1966–2008), bibliographies, and authors’ 
reference ﬁ les. Studies in which participants were randomized to statin or placebo for 
at least 4 years and coronary clinical disease or death was the primary outcome were 
included in the meta-analysis. RESULTS: Data from 4 primary and 4 secondary pre-
vention trials, with 46357 participants and 5.1 years treatment duration, were
included in this study. All patients in secondary preventions trials had a history of 
either myocardial infarction or angina. Meta-analysis revealed that statin drug treat-
ment reduced absolute risk for major coronary events per 1000 by 19 (P  0.001,
95% conﬁ dence interval [CI]: 9–29), 48 (P  0.001, 95% CI: 28–67) in primary and 
secondary prevention trials, respectively; by 3 (P  0.005, 95% CI: 1–5), 20 (P  0.001,
95% CI: 17–24) for coronary mortality; by 5 (P  0.043, 95% CI: 0–11), 25 (P 
0.001, 95% CI: 15–35) for all-cause mortality. Difference in coronary mortality and 
all-cause mortality between primary and secondary prevention trials was statistically 
signiﬁ cant since the CIs had nothing overlapped. CONCLUSIONS: This study indi-
cated that statin therapy provided a decrease in the risk of major coronary events, 
coronary mortality and all-cause mortality in both primary and second prevention 
trials; but the secondary prevention trials obtained considerably more events avoided 
due to treatment.
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OBJECTIVES: Episode Grouping is a methodology that enables health care profes-
sionals to analyze patient treatments and evaluate the quality of the treatments and 
manage the related costs. There are three procedures or treatments for a patient with 
coronary artery disease. Re-blocking an artery after a procedure directly affects the 
cost and severity of the treatment. We use statistic and probability method to examine
the information about patients with coronary artery disease and estimate the risk of 
re-blocking an artery after each procedure. METHODS: A dataset provided by an 
insurance company is used. It contained about 6,500,000 patient claims related to
year 2000–2005. Data processing is done by using SAS software and SAS codes. Then 
based on some assumptions and conditional probability the risk of re-blocking an
artery after each procedure (bare-stent, drug-eluting stent, and open bypass surgery) 
are estimated. RESULTS: Comparing the three types of procedures; bypass surgery,
drug-eluting stent, and bare stent, shows that the risk of re-blocking an artery after a 
bare stent is almost 24%, and by using the drug-eluting stent, this risk decreases to
almost 13%. Bypass surgery procedure has the lowest re-blocking rate that is less than 
7%. CONCLUSIONS: The Drug-eluting stent reduces the rate of re-blocking an artery 
to 46% compared to the bare stent. This is the main reason for shifting from the bare
stent to the drug-eluting stent and makes the drug-eluting stent more effective. But the 
rate of re-blocking after the drug-eluting stent is still about 6% more than the rate of 
re-blocking after an open bypass surgery. The main question remaining is how we 
can estimate the severity and quality of life after each procedure and justify the cost-
effectiveness of one of this procedure.
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OBJECTIVES: To determine the association between pharmacy treatments (ACE
Inhibitors (ACEI), Beta-blockers (BB)) and outcomes in patients with chronic heart
failure (CHF). METHODS: National retrospective cohort of Veterans Affairs (VA) 
patients, with at least one outpatient claim of CHF between October 1, 1996 and
September 30, 2001 (end of FY01), was identiﬁ ed. Exposure and outcomes were 
assessed in FY 2001 and FY 2002, respectively. ACEI/BB therapy was deﬁ ned as 
patients taking ACEI/BB with MPR (Medication Possession Ratio) 0.8 in exposure 
period. Outcomes were hospitalizations (all cause and heart failure) and total 
costs (inpatient, outpatient and pharmacy costs). Multivariate regression analysis 
was employed to determine outcome estimates; adjusted for socio-demographics, 
30 co-morbidities, co-medications and disease severity as measured by years with
heart failure. RESULTS: Total cohort comprised of 230,406 patients with mean 
age 69.96 o 10.39 years, 98% were men and 48% were whites. Of the total
cohort 89,757 (38.96%) were on ACEI therapy and 67,348 (29.23%) on BB therapy. 
Hypertension was the most prevalent comorbidity (78.76%). For all cause hospitaliza-
tion, BB was associated with 3.1% reduced risk (Adjusted OR: 0.969, 95% CI: 
0.944–0.994), whereas ACEI did not show any signiﬁ cant change (Adjusted OR: 1.0, 
95% CI: 0.98–1.029). For HF hospitalizations, BB reduced risk by 14.3% (Adjusted 
OR: 0.857, 95% CI: 0.812–0.904), whereas ACEI showed increased risk (Adjusted 
OR: 1.082, 95% CI: 1.029–1.137). Both therapies were associated with signiﬁ cant 
increase in costs compared to patients not receiving these medications (ACEI 5.3%, 
p  0.0001; BB 7%, p  0.0001). CONCLUSIONS: BB was associated with signiﬁ -
cantly reduced risk of all cause and HF hospitalizations, while ACEI did not show 
signiﬁ cant protective effect. Both therapies were found to increase total costs, suggest-
ing the need for more studies to examine cost-effective therapies for patients in routine 
clinical settings.
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OBJECTIVES: Statin medications are recommended for patients who have not 
achieved LDL-C goals through lifestyle modiﬁ cations. Little information exists regard-
ing the use of statins and LDL-C goal attainment among employed populations. This 
retrospective, observational study examined the statin medication usage pattern and 
the relationship between statin usage and LDL-C goal levels (according to ATP III 
guidelines) among a cohort of employees of a major ﬁ nancial services corporation.
METHODS: From 1995 to 2004, a total of 1,607 executives (average age 49.1, s.d. 
